Cited 0 times in
Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이혜원 | - |
dc.date.accessioned | 2021-12-28T17:06:19Z | - |
dc.date.available | 2021-12-28T17:06:19Z | - |
dc.date.issued | 2021-08 | - |
dc.identifier.issn | 1936-0533 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/186938 | - |
dc.description.abstract | Background: Controlled attenuation parameter (CAP) can evaluate hepatic steatosis in patients with chronic hepatitis B (CHB). However, prognostic implications of CAP value remain unclear. We evaluated the association between CAP and the risk of hepatocellular carcinoma (HCC) in patients with CHB under antiviral therapy and maintained virologic response. Methods: A total of 1823 CHB patients who were taking nucleos(t)ide analogue and showing suppressed hepatitis B virus replication were analyzed. The primary outcome was incident HCC during follow-up. Patients were grouped into those with and without advanced chronic liver disease (ACLD) (liver stiffness measurement cutoff: 10 kPa), and those with and without hepatic steatosis (CAP cutoff: 222 dB/m). Results: During 6.4 years of follow-up, 127 patients (7.0%) newly developed HCC. Among patients with ACLD (n = 382), the cumulative HCC incidence rate was lower for those with CAP ≥ 222 (11.0% at 5 years) than those with CAP < 222 (24.0% at 5 years, p = 0.002), and was an independent factor associated with HCC. When CAP value was further stratified, the cumulative HCC incidence rate decreased in dose-dependent manner according to an increase in CAP value (24.0%, 13.9%, 12.8% and 6.0% at 5 years for those with CAP < 222, 222-246, 247-273 and ≥ 274, respectively). Among patients without ACLD (n = 1441), there was no significance difference in HCC risk according to CAP value (HCC incidence rate: 3.3% and 4.0% at 5 years for those with CAP < 222 and CAP ≥ 222, p = 0.20). Conclusions: Among CHB patients under antiviral therapy showing suppressed HBV replication, low CAP value predicted higher risk for HCC among ACLD patients, indicating that CAP value has a prognostic implication in this population. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer | - |
dc.relation.isPartOf | HEPATOLOGY INTERNATIONAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antiviral Agents / therapeutic use | - |
dc.subject.MESH | Carcinoma, Hepatocellular* / drug therapy | - |
dc.subject.MESH | Carcinoma, Hepatocellular* / epidemiology | - |
dc.subject.MESH | Carcinoma, Hepatocellular* / etiology | - |
dc.subject.MESH | Elasticity Imaging Techniques | - |
dc.subject.MESH | Hepatitis B virus | - |
dc.subject.MESH | Hepatitis B, Chronic* / complications | - |
dc.subject.MESH | Hepatitis B, Chronic* / drug therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Liver Cirrhosis / drug therapy | - |
dc.subject.MESH | Liver Neoplasms* / drug therapy | - |
dc.subject.MESH | Liver Neoplasms* / epidemiology | - |
dc.subject.MESH | Liver Neoplasms* / etiology | - |
dc.subject.MESH | Risk Factors | - |
dc.title | Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Joo Hyun Oh | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Dong Hyun Sinn | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Wonseok Kang | - |
dc.contributor.googleauthor | Geum-Youn Gwak | - |
dc.contributor.googleauthor | Moon Seok Choi | - |
dc.contributor.googleauthor | Joon Hyeok Lee | - |
dc.contributor.googleauthor | Kwang Cheol Koh | - |
dc.contributor.googleauthor | Seung Woon Paik | - |
dc.contributor.googleauthor | Yong-Han Paik | - |
dc.identifier.doi | 10.1007/s12072-021-10205-7 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03318 | - |
dc.relation.journalcode | J00986 | - |
dc.identifier.eissn | 1936-0541 | - |
dc.identifier.pmid | 34260013 | - |
dc.identifier.url | https://link.springer.com/article/10.1007%2Fs12072-021-10205-7 | - |
dc.subject.keyword | Chronic hepatitis B | - |
dc.subject.keyword | Controlled attenuation parameter | - |
dc.subject.keyword | Hepatocellular carcinoma | - |
dc.subject.keyword | Transient elastography | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 김범경 | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.citation.volume | 15 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 892 | - |
dc.citation.endPage | 900 | - |
dc.identifier.bibliographicCitation | HEPATOLOGY INTERNATIONAL, Vol.15(4) : 892-900, 2021-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.